Markt geschlossen -
Andere Börsenplätze
|
Nachbörslich 22:22:18 | |||
733,5 USD | +1,19 % | 732,1 | -0,19 % |
15:55 | Pharmafirma Cheplapharm mit Rekordumsatz | DP |
25.04. | Scholz sichert Pharmabranche weiter Unterstützung zu | DP |
Kurzporträt
- Endokrinologie (57,7%): Produkte zur Behandlung von Osteoporose, Diabetes und Wachstumsstörungen;
- Onkologie (19,5%);
- Immunologische Erkrankungen (11,1%);
- Neurologie (8,4%): hauptsächlich Medikamente zur Behandlung von Depressionen und Schizophrenie;
- Sonstige (3,3%).
Der Nettoumsatz verteilt sich geografisch wie folgt: Vereinigte Staaten (63,9%), Europa (18,1%), Japan (4,9%), China (4,5%) und Sonstige (8,6%).
Mitarbeiterzahl: 43 000
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Human Pharmaceutical Products
100,0
%
| 28 541 | 100,0 % | 34 124 | 100,0 % | +19,56 % |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
63,9
%
| 18 190 | 63,7 % | 21 791 | 63,9 % | +19,80 % |
Europe
18,1
%
| 4 299 | 15,1 % | 6 175 | 18,1 % | +43,62 % |
Other Foreign Countries
8,6
%
| 2 852 | 10,0 % | 2 946 | 8,6 % | +3,30 % |
Japan
4,9
%
| 1 747 | 6,1 % | 1 673 | 4,9 % | -4,28 % |
China
4,5
%
| 1 453 | 5,1 % | 1 540 | 4,5 % | +5,98 % |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01.01.96 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 01.01.01 |
Ruth Gimeno
PSD | President | - | - |
Diogo Rau
CTO | Chief Tech/Sci/R&D Officer | - | 17.05.21 |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 16.10.23 |
Alonzo Weems
CMP | Compliance Officer | - | 01.01.97 |
Chief Tech/Sci/R&D Officer | 50 | 01.01.18 | |
Corporate Officer/Principal | - | 01.01.05 | |
Ilya Yuffa
PRN | Corporate Officer/Principal | 49 | - |
Ronald DeMattos
PRN | Corporate Officer/Principal | - | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Director/Board Member | 63 | 25.01.21 | |
Ralph Alvarez
BRD | Director/Board Member | 67 | 01.04.09 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 01.01.05 |
Juan Luciano
BRD | Director/Board Member | 62 | 01.02.16 |
William Kaelin
BRD | Director/Board Member | 66 | 04.06.12 |
David Ricks
CEO | Chief Executive Officer | 56 | 01.01.96 |
Jamere Jackson
BRD | Director/Board Member | 54 | 01.10.16 |
Director/Board Member | 52 | 12.12.11 | |
Marschall Runge
BRD | Director/Board Member | 69 | 01.09.13 |
Karen Walker
BRD | Director/Board Member | 62 | 01.12.18 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 951 168 100 | 949 200 653 ( 99,79 %) | 402 000 ( 0,0423 %) | 99,79 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
IMMUNOCORE HOLDINGS PLC 6,25% | 2 548 145 | 6,25% | 165 629 425 $ |
8 084 411 | 6,83% | 50 324 488 $ | |
PROQR THERAPEUTICS N.V. 16,55% | 13 371 562 | 16,55% | 30 620 877 $ |
4 000 000 | 9,40% | 26 840 000 $ | |
21 776 804 | 7,60% | 11 630 773 $ | |
AC IMMUNE SA 3,64% | 3 615 328 | 3,64% | 10 701 371 $ |
125 405 | 1,91% | 1 700 492 $ |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Eli Lilly SA
Eli Lilly SA Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly SA is a Swiss company that manufactures medicines. The private company is based in Vernier, Switzerland. |
Pharmaceuticals: Major
|
Kinsale Financial Services
| |
ELI Lilly & Company (India) Pvt Ltd.
ELI Lilly & Company (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology ELI Lilly & Company (India) Pvt Ltd. manufactures and markets pharmaceutical products. The firm's products treat diabetes, gastric cancer, lung cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency. The company was founded in 1993 and is headquartered in Gurgaon, India. |
Pharmaceuticals: Major
|
Lilly Ventures Fund I LLC
Lilly Ventures Fund I LLC Investment ManagersFinance Lilly Ventures Fund I LLC seeks investment opportunities located in the North American and European regions. The fund targets companies operating in the fields of biotechnology, medical technology and healthcare IT. It provides financing for early stage capital requirements. |
Investment Managers
|
Eli Lilly Export SA (Switzerland)
Eli Lilly Export SA (Switzerland) Medical DistributorsDistribution Services Part of Eli Lilly & Co., Eli Lilly Export SA is a pharmaceutical company based in Vernier, Switzerland. The Swiss company combines care with research to develop innovative solutions for a better life worldwide. |
Medical Distributors
|
Eli Lilly Group Pension Trustees Ltd.
Eli Lilly Group Pension Trustees Ltd. Financial ConglomeratesFinance Part of Eli Lilly & Co., Eli Lilly Group Pension Trustees Ltd. operates as a British dormant company. The private company is based in Basingstroke, UK. |
Financial Conglomerates
|
Eli Lilly (Suisse) SA
| |
Eli Lilly Vostok SA
| |
Eli Lilly Services India Pvt Ltd.
Eli Lilly Services India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Services India Pvt Ltd. is an Indian company that discovers, develops, manufactures and sells pharmaceutical products. The private company is based in Bangalore, India and was founded in 2015. |
Pharmaceuticals: Major
|
Sektor
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+26,30 % | 653 Mrd. | |
+27,00 % | 556 Mrd. | |
-6,44 % | 354 Mrd. | |
+20,40 % | 331 Mrd. | |
+3,76 % | 296 Mrd. | |
+13,09 % | 233 Mrd. | |
+5,46 % | 201 Mrd. | |
-9,61 % | 193 Mrd. | |
-6,20 % | 144 Mrd. | |
-11,81 % | 143 Mrd. |
- Börse
- Aktien
- 858560 Aktie
- Unternehmen Eli Lilly and Company